Lindox-L Capsule is a combination pharmaceutical formulation containing Doxycycline 100 mg and Lactobacillus 5 billion spores, designed to provide effective antibacterial therapy alongside probiotic support. Doxycycline, a broad-spectrum tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby preventing the growth and replication of susceptible bacteria. It is commonly indicated for the treatment of respiratory tract infections, urinary tract infections, skin infections, and certain sexually transmitted infections. The inclusion of Lactobacillus spores serves to maintain and restore the natural intestinal flora, which may be disrupted during antibiotic therapy, thereby reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Lindox-L Capsule is particularly beneficial in managing infections where maintaining gut microbiota balance is crucial. The probiotic component also supports immune function and enhances intestinal health. This combination therapy should be administered under medical supervision, with dosage and duration tailored to the specific infection and patient condition. Contraindications include hypersensitivity to tetracyclines or probiotics, and caution is advised in pregnant or lactating women. Adverse effects may include gastrointestinal discomfort, photosensitivity, and allergic reactions. Lindox-L Capsule represents a synergistic approach to infection management, combining antimicrobial efficacy with probiotic protection.